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Abstract: Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively
treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with
Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis,
and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who
are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be
challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we
describe the results of our investigation into the development of alginate/chitosan particles prepared
via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan
particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit
P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte
protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung
infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic
fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro,
which have prospects to enhance their efficacy in vivo.
Keywords: biomedical applications; drug delivery systems; particles; antimicrobial
1. Introduction
Cystic fibrosis (CF) is a complex, potentially life-threatening disease which is manifested through
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) [1]. The protein product
of this gene functions as a cyclic adenosine monophosphate (cAMP)-dependent transmembrane
chloride (Cl−) channel. It is responsible for the transport of ions across the apical membrane of exocrine
epithelial cells [2]. The protein shows widespread expression across the epithelial lining of most
exocrine glands, though it is mainly expressed in cells of the small intestine, airways, vas deferens and
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ducts of the pancreas [3–6]. The mutations present in the CFTR gene have been shown to lead to the
subsequent loss of Cl− transport in these cell types. The pulmonary environment has been shown to be
one of the most largely effected by the loss of Cl− channel activity [7] concomitant with a decrease
in volume of the airway surface liquid (ASL) causing the accumulation of thickened mucus in the
pulmonary environment (Figure 1) [8,9]. This is believed to increase the susceptibility of the lung to
infection by organisms including Pseudomonas aeruginosa, Haemophilus influenza and Staphylococcus
aureus [10]. Early infecting strains such as S. aureus are usually cleared by antibiotic therapy, though
they are believed to facilitate chronic colonisation by P. aeruginosa [11]. Chronic colonisation with
P. aeruginosa coincides with increasing antibiotic resistance and the emergence of P. aeruginosa as the
dominant infecting organism over time [12].
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Figure 1. Events linking altered lung airway surface layer (ASL) volumes to decreased mucociliary
clearance. (A) Normal airway surfaces contain a small mucus layer which facilitates entrapment of
inhaled particles and pathogens. ASL autoregulation leads to the maintenance of the pericilliary
liquid layer (PCL) which allows movement and clearance of inhaled particles and pathogens.
(B) Hyperabsorption of Na+ and ineffective Cl− secretion in the cystic fibrosis (CF) airway cause
depletion of ASL, collapse of the cilia in the PCL and adherence of concentrated mucus in the airways.
Chronic infection with P. aeruginosa is one of the most significant events in the pathogenesis of
cystic fibrosis [13]. Tobramycin is the treatment of choice for those patients with chronic P. aeruginosa
infection who are deteriorating despite regular colistimethate sodium [14,15]. It is one of the most
effective treatments for pulmonary exacerbations and is generally delivered through nebulisation at
a dose of 300 mg twice daily. The pharmacokinetic parameters are similar to other aminoglycoside
drugs resulting in rapid renal excretion [16]. As with other aminoglycosides, tobramycin shows no
activity against gram positive organisms such as S. aureus, therefore early CF antibacterial therapies
often focus on administration of anti-staphylococcal prophylactic antibiotics [17].
Clinical treatment with tobramycin involves twice daily administration of high doses of the
drug due to its high absorption and short plasma half-life [18]. One of the main problems with CF
therapy is non-compliance. Non-compliance with antibiotic regimens can lead to antibiotic failure [19],
therefore altering the dosing schedule of tobramycin from twice daily to once daily may in part address
compliance issues. Another concern with prolonged tobramycin treatment is the potential toxicity
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experienced due to the ototoxic and nephrotoxic property of the drug [20,21]. Nephrotoxicity is often
associated with parenteral aminoglycoside therapy, but there is limited evidence of nephrotoxicity and
ototoxicity in clinical trials with nebulised tobramycin [22]. With longer durations of therapy there
is an increased potential risk of nephrotoxicity. Therefore, the development of delivery systems for
tobramycin which could reduce the dosing frequency of the drug while also reducing systemic toxicity
upon prolonged exposure may be of clinical benefit.
The CF lung provides a further barrier to efficient drug delivery due to the presence of a thick
mucus layer on the epithelial lining [23]. This is due to the altered salt transport system within the CF
lung, which results in increased dehydration and mucus viscosity with delayed mucus clearance [24].
Furthermore, P. aeruginosa forms a thick alginate-based biofilm which provides increased resistance to
antibacterial therapy [11].
A further complication arises from the enhanced pro-inflammatory response to infection which
causes increased infiltration of neutrophils to the site of bacterial colonisation [25]. Neutrophils
promote the pro-inflammatory response to infection through the release of various pro-inflammatory
proteases such as neutrophil elastase (NE) which can overload the endogenous anti-protease host
defenses, leading to tissue damage and loss of respiratory function [12]. There is therefore interest
in the development of drug delivery systems which can enhance the antibacterial activity of the
delivered payload through increased accumulation at the site of infection while reducing the aberrant
inflammatory response to infection.
The secretory leukocyte protease inhibitor (SLPI) is an 11.7 kDa protein which is naturally
expressed as part of the innate immune response in humans [26]. SLPI is naturally expressed in
a number of bodily secretions including nasal, pulmonary, salivary and seminal secretions [27–30].
SLPI has been shown to display potent anti-inflammatory activity through inhibition of a number
of endogenous serine proteases including NE [31]. Due to the high association rate constant for NE
it is believed SLPI acts as the primary inhibitor of NE in vivo [12]. Studies have shown therapeutic
administration of recombinant SLPI (r-SLPI) to CF patients can reduce the inflammatory response by
lowering active levels of NE while also reducing NE mediated interleukin 8 (IL-8) production, which is
involved in the recruitment of pro-inflammatory mediators to the site of disease [32,33]. SLPI has also
been shown to reduce inflammation through inhibition of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) signaling [34].
Here we describe the results of our investigation on the development of alginate/chitosan particles
for pulmonary applications. In the first paradigm, tobramycin loading and release was investigated,
and in the second paradigm the particles were functionalised with SLPI to help inhibit the inflammatory
response associated with infection (and potentially passively target the particles through binding with
anionic mucins within mucus to provide enhanced targeting to the site of disease due to its cationic
nature).
2. Materials and Methods
2.1. Materials
Unless otherwise noted, all chemicals (including Calbiochem neutrophil elastase substrate
(methoxysuccinyl-l-alanyl-alanyl-prolyl-l-valyl-4-nitroanilide)) were obtained from Sigma Aldrich,
Gillingham, UK. Boric acid, calcium chloride hexahydrate, ethanol and the Pierce bicinchoninic acid
(BCA) protein assay kit were purchased from Fisher Scientific UK, Loughborough, UK. Tryptone,
sodium chloride (bacteriological grade) and yeast extract were purchased from Oxoid Ltd., Basingstoke,
England. Recombinant human neutrophil elastase was purchased from the Elastin Products Company
(EPC) Owensville, MO, USA. Recombinant human secretory leukocyte protease inhibitor (SLPI) was
purchased from Amgen, Cambridge, UK. Biotinylated anti-human SLPI antibody was purchased from
R&D Systems, Abingdon, UK. Sputum from CF patients was obtained anonymously from the adult
CF centre at Belfast City Hospital. Sputum samples were in excess to requirements for diagnostic
Pharmaceutics 2019, 11, 379 4 of 12
purposes. Permission to use sputum samples (which would have been disposed of) for validation
purposes was given by the director of R&D in Belfast Health and Social Care Trust.
2.2. Preparation of Tobramycin Loaded Alginate/Chitosan Particles
Several formulations of tobramycin were tested for their ability to formulate tobramycin loaded
particles with no aggregation (Table 1). CaCl2 and chitosan were utilised as cationic crosslinkers.
Tobramycin was included in all formulations. Briefly, aqueous solutions of tobramycin (1.5 mg in
3 mL) were added to various amounts of sodium alginate (pH 5.4) while stirring (500 rpm) at room
temperature. 1 mL of chitosan (1% v/v glacial acetic acid, pH 5.1) at various concentrations was
added dropwise (over ca. 5 min) from a syringe fitted with a 25G needle while stirring (500 rpm).
The particle suspension was collected by centrifugation for 30 min at 20,000 g, after which the pellet
of particles was resuspended in PBS and collected by centrifugation for 30 min at 20,000 g, this
resuspension/centrifugation process was repeated twice more.
2.3. Particle Characterisation
The size distribution (polydispersity index; PDI) and zeta potential of the particles was determined
by dynamic light scattering (DLS) using a Malvern Zetasizer (Nano ZS; Malvern instruments, Malvern,
UK). For particle analysis, each sample was read in triplicate (10 runs each). The average of three
separate samples was taken and the data presented as the mean ± standard deviation. Transmission
electron microscopy (TEM) was performed using a JEOL JEM1400 (JEOL, Inc. Peabody, MA, USA)
transmission electron microscope at an accelerating voltage of 80 kV. Particles (0.6 mg/mL) were loaded
on a copper grid (Formvar/Carbon 200 µm mesh, Agar Scientific Ltd., Stansted, UK), the moisture
wicked off and allowed to dry. 2 µL of uranyl acetate (2% w/v) was added to provide contrast between
the particles and copper grid.
2.4. Conjugation of SLPI to Chitosan
Chitosan 0.5 mL (2 mg/mL, in 1% v/v glacial acetic acid) was diluted 1:1 in PBS buffer (25 mM,
pH 7.4) and 10 µL of SLPI was added (25 mg/mL). The pH of the solution was adjusted to 5 and the
conjugation was initiated by the addition of 1-ethyl-3-(dimethylaminopropyl carbodiimide) (EDC)
(2.5 mg/mL) and left stirring for 6 h at room temperature. The SLPI/chitosan conjugate was used
instantly for particle formation with alginate and excess EDC was removed by washing of the particles
through centrifugation/resuspension cycles (assaying for EDC via thin layer chromatography, TLC).
2.5. Quantification of SLPI Conjugation
Particles were formulated as described previously and centrifuged at 20,000 g. The supernatant
was collected. Blank particles (not conjugated to SLPI) were also included as a control. The levels of
SLPI conjugation achieved were measured with the BCA assay kit. 25 µL of control and conjugate
particles (10 mg/mL) were added to 175 µL of BCA reagent A (sodium carbonate, sodium bicarbonate,
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and B (4% W/W cupric sulphate
in water) in a 96 well plate. The plate was then incubated for 60 min at 37 ◦C. The absorbance of the
resultant solution was read at 570 nm and compared to a calibration curve of SLPI.
2.6. Analytical Methodology for Detection of Tobramycin Sulphate
Reagent A, consisting of 80 mg of ortho-phthaldialdehyde in 1 mL of 95% ethanol, and reagent B,
containing 200 µL of boric acid (pH 9.7, 0.4 M), 400 µL β-mercaptoethanol and 200 µL of diethyl ether
were mixed. Serial dilutions of tobramycin were prepared in boric acid (pH 9.7, 0.4 M). 100 µL of each
tobramycin standard was added to 100 µL of the reagent mixture. The plate was read by fluorescence
at λex/λem 360/460 nm, respectively.
Pharmaceutics 2019, 11, 379 5 of 12
2.7. Quantification of Tobramycin Release
Drug release was quantified by incubating the particles in dialysis membranes with a 10,000 Da
MWCO (Thermo Fisher Scientific, Heysham, UK) at 37 ◦C with agitation. The release of the tobramycin
was quantified by incubating 3 mg of particles in 1 mL of PBS in the donor compartment with 5 mL
of PBS in the receiver compartment. At each time point the PBS was collected and replaced with
fresh PBS release medium. Quantification of the tobramycin release was performed by diluting the
release medium 1:1 with boric acid (0.4 M pH 9.7) prior to derivatisation with ortho-phthaldialdehyde
(80 mg) in a solution containing 1 mL of 95% ethanol, 200 µL boric acid (0.4 M pH 9.7), 400 µL of
β-mercaptoethanol and 200 µL diethyl ether. The fluorescent derivative was monitored by fluorescence
at λex/λem 360/460 nm, respectively using a BMG-LABTECH Fluorstar Optima fluorescent plate reader
(BMG-LABTECH, Aylesbury, UK).
2.8. Minimum Inhibitory Concentration Effect of Tobramycin on P. aeruginosa
Broth micro-dilution tests were performed according to National Committee for Clinical Laboratory
Standards (NCCLS) guidelines. Serial two-fold dilutions of tobramycin (from stock solution which
had been sterile filtered with 0.22 µm filter) in 100 µL of Luria Bertani (LB) broth were performed
on a 96 well plate in the range 0–25 µg/mL for the drug loaded particles, free tobramycin and the
blank particles as negative control. The actively growing cultures were diluted to an optical density
reading of 0.3 (A550) to give a starting inoculum of 2 × 105 CFU/mL. 100 µL of the starting inoculum
(2 × 105 CFU/mL) was added to each well of the plate and incubated aerobically at 37 ◦C for 24 h.
Positive and negative controls were included in each assay.
2.9. Inhibition of Neutrophil Elastase by SLPI Functionalised Alginate/Chitosan Particles
Anti-neutrophil elastase activity was monitored by incubation with the human neutrophil
elastase (HNE) specific substrate methoxysuccinyl-Ala-Ala-Pro-Val-P-nitroanilide (Sigma, Aldrich,
UK). Inhibitions of HNE (Elastin products, Owensville, MO, USA) were measured in the presence
and absence of both blank and SLPI conjugated particles. The assay was carried out by incubating
10 µL (10 mg/mL particles) of blank and SLPI conjugated particles containing 100 µg/mL SLPI
with 4 µL of HNE (100 µg/mL). HNE activity was measured by the cleavage of chromogenic
methoxysuccinyl-Ala-Ala-Pro-Val-P-nitroanilide substrate by adding 50 µL of 0.2 mM substrate
in 0.1 M HEPES buffer containing 0.5 M NaCl. Assays were conducted at 37 ◦C and the formation
of the fluorescent product (p-nitroaniline) was measured continuously at 405 nm on a BMG-Labtech
Fluorstar Optima fluorescent plate reader.
2.10. Preparation of Rhodamine 6G Loaded Alginate/Chitosan Particles
3 mL of a tobramycin stock solution in water (0.5 mg/mL) was added to 3 mL of sodium alginate
(3 mg/mL pH 5.4). 250 µL of rhodamine 6G (2 mg/mL) was then added to the tobramycin alginate
mixture. 1 mL of chitosan (1% v/v glacial acetic acid pH 5.1) was added dropwise from a syringe fitted
with a 25G needle while stirring (500 rpm). The particle suspension was collected by centrifugation
for 30 min at 20,000 g, after which the pellet of particles was resuspended in PBS and collected by
centrifugation for 30 min at 20,000 g, this resuspension/centrifugation process was repeated twice more.
2.11. Penetration of SLPI Functionalised Particles in CF Mucus
The penetration of rhodamine loaded particles with and without SLPI functionalisation was
studied in CF mucus. A 500 µL layer of 10% gelatin (Porcine type A Sigma- Aldrich) was added to
a 24 well microplate and allowed to harden. 500 µL of CF sputum or PBS control was added and
allowed to settle. 200 µL of SLPI functionalised particles (10 mg/mL) were added to the sputum and
PBS control wells with SLPI at a concentration of 100 µg/mL. Non-conjugated rhodamine loaded
particles were diluted to give an equivalent concentration of rhodamine. Particle penetration was
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measured over 24 h after which the gelatin layers were washed (PBS × 6) and the gelatin was melted
and fluorescence measured at 480/520 nm. Penetration in CF mucus was measured by comparison
to the PBS control which was measured as 100% penetration. Fluorescent values were analysed in
reference to rhodamine 6G standards in the range (0–1000 ng/mL).
2.12. Statistical Analysis
Experiments were repeated in triplicate and reported as mean ± standard deviation (S.D.). Results
were analysed with GraphPad Prism, version 8.02, GraphPad Software (San Diego, CA, USA). T-test
analysis was performed as appropriate. Statistical significance critical values were defined as ** p < 0.01,
*** p < 0.0001.
3. Results and Discussion
We have an interest in the development of particles designed for therapeutic application in
diseases such as cystic fibrosis (CF) [35].
3.1. Particle Preparation and Tobramycin Loading and Release
Various particle-based drug delivery systems have been developed to facilitate the effective
delivery of drugs to the pulmonary system [36]. Here we report the development of tobramycin-loaded
particles composed of alginate and chitosan. The results of varying the ratio of the components
(alginate:chitosan:tobramycin:CaCl2) on particle formation are reported in Table 1.
Table 1. Optimisation of formulation parameters in the design of alginate/chitosan particles. Results
presented as mean ± standard deviation (S.D.), N = 3.
Alginate
(w/w Ratio)
Chitosan
(w/w Ratio)
Tobramycin
(w/w Ratio)
CaCl2
(w/w Ratio) Aggregation
9 1.5 1.5 3 Yes
9 1.5 1.5 0.8 Yes
9 0.8 0.8 0 No
9 1 3 0 Yes
9 1 1.5 0 No
During the optimisation studies we observed that a higher concentration of cations in the
formulation resulted in the aggregation of the particles (Table 1). The optimal formulation of
alginate:chitosan:tobramycin 9:1:1.5 (w/w/w), resulted in the formation of particles with a fairly narrow
size distribution and high loading of tobramycin (Table 2, Figures S1 and S2) and was therefore used
for further studies. The particle size distribution assessed by DLS measurements (Table 2, Figure S1)
were somewhat larger than those observed by TEM (Figure S2), however, the DLS data was judged to
be more representative of the whole population of particles as the particles are hydrated.
Tobramycin loading (Table 2) and release (Figure S3) was quantified by fluorimetry after
derivatisation of the tobramycin with ortho-phthaldialdehyde [37] (the calibration curve is depicted in
Figure S4); a typical biphasic release was observed with 18.9% of the entrapped tobramycin released
within the first 24 h, although the overall release was limited to 25.4% of the total amount of loaded
tobramycin over the course of the experiment. The optimal formulation of the tobramycin-loaded
alginate/chitosan particles was tested against live cultures of P. aeruginosa (Figure 2). The unloaded
particles showed no activity against P. aeruginosa, tobramycin alone had a Minimum inhibitory
concentration (MIC) of 1.5 µg/mL, and the tobramycin-loaded particles showed activity in a dose
dependent manner as expected, with a somewhat elevated MIC of 6.25 µg/mL, which was likely to be
due to the rate of diffusion of tobramycin from the particles. While this would still be compatible with
the delivery of a clinically relevant dosage (of 300 mg twice daily) to be delivered as the biopolymers
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are biocompatible, future studies will be directed towards improving the release profiles by tuning the
crosslinking density of the particles.
Table 2. Properties of the particles prepared with the optimal formulation of alginate:chitosan:tobramycin
(9:1:1.5, w/w/w). Results presented as mean ± S.D, N = 3.
Particle Size (nm) PDI Zeta Potential (mV) Tobramycin Loading inParticles (µg/mg) % Entrapment
437.5 ± 22.3 0.27 ± 0.07 21.6 ± 1.1 74.2 ± 3.4 44.5 ± 2.0
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Figure 2. Minimum inhibitory concentration (MIC) analysis of tobramycin-loaded alginate/chitosan
particles against P. aeruginosa. (A) Unloaded particle control. (B) Free tobramycin. (C) Tobramycin
loaded particles. Mean values ± S.D, N = 3.
3.2. SLPI-Conjugated Particle Preparation and Interactions with Model Biological Milieu
Disease states such as CF are characterised by increased infiltration of pro-inflammatory cytokines
in the lung [25] which leads to extensive tissue damage through NE mediated activity [12]. As a natural
inhibitor of NE [31] it was anticipated that the conjugation of SLPI to the particles could potentially
inhibit NE mediated tissue destruction while also achieving passive targeting for the particles.
The bioconjugation was achieved via carbodiimide chemistry. The properties of particles prepared
with SLPI in the absence/presence of carbodiimide crosslinker are displayed in Table 3 (and Figure S5),
with particles formed in the absence of carbodiimide containing 0.2 µg of SLPI, whereas those formed
in the presence of carbodiimide containing 11.2 µg of SLPI, highlighting the necessity of using the
carbodiimide to attach the SLPI to the particles.
Table 3. Particle properties following preparation without/with carbodiimide. Results presented as
mean ± S.D, N = 3.
Crosslinker
(EDC)
Particle Size
(nm)
Polydispersity Index
(PDI)
Zeta Potential
(mV)
Conjugated SLPI (µg) in Particles
(mg), (µg/mg)
No 437.5 ± 26.5 0.26 ± 0.09 −22.9 ± 3.1 0.2 ± 0.3
Yes 458.0 ± 31.1 0.31 ± 0.12 −19.2 ± 2.1 11.2 ± 2.3
To evaluate whether any of the conjugated SLPI was functional after conjugation to
the chitosan in the particles, the SLPI-conjugated particles were incubated with human
neutrophil elastase (NE) and their ability to inhibit the cleavage of a chromogenic substrate
(methoxysuccinyl-Ala-Ala-Pro-Val-P-nitroanilide) was studied [38] and compared to free SLPI and
unmodified particles (Figure 3). The unmodified/blank alginate/chitosan particles show very little
NE inhibitory activity (similar to NE alone), by contrast the SLPI conjugated particles displayed
a similar level of activity to the free SLPI, confirming that the SLPI retains NE inhibitory activity when
conjugated to the particles.
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Figure 3. Inhibition of neutrophil elastase (NE) by secretory leukocyte protease inhibitor (SLPI)-conjugated
particles. Results presented as mean ± S.D, N = 3.
In order to effectively treat P. aeruginosa infections it is necessary for drugs to achiev therapeutic
concentrations at the site of bacterial colonisation. P. aeruginosa has been shown to reside within the thick
mucus secretions within the CF lung [39]. We anticipated that the conjugation of SLPI to the particles
could enhance their mucoadhesive properties via electrostatic interactions [40]. The penetration of
SLPI-conjugated particles into CF mucus was assessed using rh damine-loaded particles (Figure 4
and Figure S6) in accordance with a protocol found in the literature [41]. We observed that the SLPI
conjugated particles entrapping rhodamine dye were retained to a greater level in CF sputum over the
non-conjugated particles. Only 19.4% of particles functionalised with SLPI were shown to traverse CF
mucus as opp sed to 29.7% of particle wi out SLPI (in line with literature showing particles with
cationic coatings could be retained within the pulmonary environment longer, thereby increasing the
therapeutic efficacy of the drug) [42].
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environment longer, thereby increasing the therapeutic efficacy of the drug) [42]. 
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3.3. Applicability
Chronic infection with P. aeruginosa is of key importance in CF pathogenesis [13], and if treatment
with colistimethate sodium is ineffective it is treated by the nebulisation of tobramycin at a dose of
300 mg twice daily [14,15,18]. Akin to many conditions, problems with CF therapy include systemic
toxicity and non-compliance of the patients [19], however, its treatment is further complicated by the
accumulation of thickened mucus in the pulmonary environment. Consequently, the generation of
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drug delivery systems capable of tailoring the therapeutic delivery paradigm has significant potential
for clinical benefits [43–49].
Herein we have described the results of our preliminary investigation of the development of
alginate/chitosan particles for tobramycin delivery to pulmonary environments. Tobramycin loading
and release from the alginate/chitosan particles was investigated, with evidence of both uptake and
release of sufficient tobramycin to inhibit P. aeruginosa in vitro; albeit with room for improvement to the
quantity/speed of delivery that could be achieved by tuning the crosslinking density of the particles.
Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI)
was shown to help inhibit the inflammatory response associated with lung infections (via inhibition
of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed
via reduction of the depth of particle penetration into the mucus) in vitro. These results highlight
our capability to develop drug delivery systems which can enhance the antibacterial activity of the
delivered payload through increased accumulation at the site of infection while reducing the aberrant
inflammatory response to infection [11,12,23–25,32–34]. These findings have potential to be used
much more broadly in the development of a variety of pharmaceutical formulations for pulmonary
applications in academia and industry, with potential for eventual clinical translation after significant
further research and development to optimise properties and dosing methodology.
4. Conclusions
The complexity of CF treatment regimens has been shown to be largely responsible for patient
non-compliance [19,50], and the formulation of particles displaying mucoadhesive properties is
a potential solution to minimise problems associated with non-compliance, with potentially significant
beneficial economic, health and societal impacts at the global scale. The particles described herein
were capable of delivering a potent antimicrobial (tobramycin) to P. aeruginosa, and the conjugation
of SLPI enhanced their mucoadhesive properties [39,42], potentially increasing the efficacy of drug
delivery over prolonged periods, and thereby potentially helping to minimise problems associated
with non-compliance after successful pre-clinical and clinical studies [51,52].
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